Latest Audit News

Carma Limited posted a 59% revenue jump to $113.8 million in FY26, doubling gross profit to $10.5 million, while gearing up to double reconditioning capacity and target positive EBITDA in 2027.

Vectus Biosystems has reported a striking turnaround with a $1.56 million profit for the 2026 financial year, reversing a prior year loss and improving its balance sheet significantly.

Michael Hill International delivered a landmark FY26 with record revenue of AU$655.7 million, a 57% jump in comparable EBIT, and reinstated dividends after a strategic turnaround.

RemSense Technologies reported a 27% revenue decline in FY2026 to $2.49 million due to project timing and economic uncertainty but secured major Tier-1 contracts and raised $1.21 million to fund technology development.

United Overseas Australia Ltd (ASX:UOS) reported a 10.3% rise in half-year revenue to $124.65 million for the period ended 30 June 2026, while net profit after tax fell 7.7% to $41.17 million. The company announced a combined interim and special dividend totaling 2.0 cents per share.

Clime Capital Limited (ASX:CAM) reported a sharp turnaround for FY26, with net profit after tax soaring 236% to $10.29 million, driven by strong unrealised gains and a higher income portfolio. The company sustained its steady dividend payments and pressed ahead with an active share and convertible note buyback program.

KKR Credit Income Fund has released the audited financial statements for its core investments as of December 31, 2025, revealing mixed returns and ongoing portfolio adjustments across multiple funds.

Orion Equities (ASX:OEQ) returned to profitability in FY26 with a $204,000 net profit, buoyed by a $400,000 uplift in investment property value. Despite a 7% dip in total revenue, net tangible asset backing per share edged up to $0.43, while no dividend was declared.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

RooLife Group (ASX: RLG) reported a 268% jump in FY2026 revenue to nearly $10 million, driven by rapid growth in its own food and beverage products, including RLG Coffee in China. Despite this, the company recorded a $3.58 million net loss, weighed down by impairment charges and R&D investments in renewable energy.

Moonlight Resources Ltd (ASX: ML8) completed its first year as a listed entity, rapidly expanding its gold and copper exploration at the Clermont Project in Queensland. The company reported a net loss of $1.98 million for FY2026, reflecting active exploration and corporate growth following its December 2025 IPO.

Dominion Income Trust 1 (ASX:DN1) delivered a standout performance for the year ended 30 June 2026, generating a 7.32% net return and sharply higher distributions, significantly outperforming its benchmark.